Verona Pharma PLC Posting of Annual report & Notice of AGM (9721Z)
March 20 2017 - 8:55AM
UK Regulatory
TIDMVRP
RNS Number : 9721Z
Verona Pharma PLC
20 March 2017
Verona Pharma plc
("Verona Pharma" or the "Company")
2016 Annual Report and Accounts
and
Notice of AGM
20 March 2017, London - Verona Pharma plc (AIM: VRP.L), a
clinical-stage biopharmaceutical company focused on developing and
commercialising innovative therapeutics for the treatment of
respiratory diseases with significant unmet medical needs, is
pleased to confirm that a hard copy of the Annual Report and
Accounts for the year ended 31 December 2016 ("2016 Annual Report
and Accounts"), the Notice of Annual General Meeting and a Form of
Proxy have been posted to Shareholders.
The Company confirms that its 2016 Annual Report and Accounts
are available online at:
http://www.veronapharma.com/investors/#investors-financial-performance.
The Notice of Annual General Meeting can be found within the AIM
Rule 26 section of the website.
The Annual General Meeting of Verona Pharma will be held at the
offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch
Street, London EC3V 0HR on 12th April 2017 at 12.00 noon.
-Ends-
For further information please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer
N+1 Singer Tel: +44 (0)20 7496 3000
Aubrey Powell / James White/ Alex Laughton-Scott
FTI Consulting Tel: +44 (0)20 3727 1000
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Notes to Editors
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company
focused on developing and commercialising innovative therapeutics
for the treatment of respiratory diseases with significant unmet
medical needs.
Verona Pharma's product candidate, RPL554, is a first-in-class,
inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4
that acts as both a bronchodilator and an anti--inflammatory agent
in a single compound. In clinical trials, treatment with RPL554 has
been observed to result in statistically significant improvements
in lung function as compared to placebo and has shown clinically
meaningful and statistically significant improvements in lung
function when added to two commonly used bronchodilators as
compared to either bronchodilator administered as a single agent.
Verona Pharma is developing RPL554 for the treatment of chronic
obstructive pulmonary disease (COPD), cystic fibrosis, and
potentially asthma.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKMGZFFGMGNZM
(END) Dow Jones Newswires
March 20, 2017 09:55 ET (13:55 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024